Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Novel therapy in the treatment of scleroderma
Autore:
Wigley, FM; Sule, SD;
Indirizzi:
Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA Johns Hopkins Univ Baltimore MD USA 21205 umatol, Baltimore, MD 21205 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 1, volume: 10, anno: 2001,
pagine: 31 - 48
SICI:
1354-3784(200101)10:1<31:NTITTO>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; PROGRESSIVE SYSTEMIC-SCLEROSIS; RECOMBINANT INTERFERON-GAMMA; ORAL PROSTACYCLIN ANALOG; COLLAGEN TYPE-I; RAYNAUDS-PHENOMENON SECONDARY; HIGH-DOSE CYCLOPHOSPHAMIDE; PLASMA ENDOTHELIN-1 LEVELS; ACETYL-L-CYSTEINE; DOUBLE-BLIND;
Keywords:
angiotensin II inhibitors; cytokines; halofuginone; inflammation; minocycline; D-penicillamine; pentoxifylline; scleroderma;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
129
Recensione:
Indirizzi per estratti:
Indirizzo: Wigley, FM Johns Hopkins Univ, Sch Med, Div Rheumatol, Suite 7300,1830 E Monument St,Baltimore, MD 21205 USA Johns Hopkins Univ Suite 7300,1830 E Monument St Baltimore MD USA 21205
Citazione:
F.M. Wigley e S.D. Sule, "Novel therapy in the treatment of scleroderma", EXPERT OP I, 10(1), 2001, pp. 31-48

Abstract

While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 15:00:12